Komipharm Applies for Oral COVID-19 Clinical Trial
[Asia Economy Reporter Minwoo Lee] Comipharm announced on the 25th that it has applied to the Pakistan Drug Regulatory Authority (DRAP) for a Phase 1 clinical trial plan involving two cohorts receiving oral administration of PAX-1 (oral) for patients with moderate COVID-19 infection.
Hot Picks Today
"Samsung Electronics Employee with 100 Million Won Salary Receiving 600 Million Won Bonus... Estimated Tax Revealed"
- "Only Two Per Person" Garbage Bag Crisis Was Just Yesterday... Japan Also Faces Shortage Anxiety
- Lived as Family for Over 30 Years... Daughter-in-Law Cast Aside After Husband's Death
- Despite ‘Tank Day’ Controversy, Gwangju Schools Purchased Starbucks Gift Certificates
- "Wore It Once, Then This? White Spots All Over 4.15 Million Won Prada Jacket... 'Full Refund Ordered'"
The company stated, "The purpose of the clinical trial is to determine the dosage confirming the safety and efficacy of Panafix in COVID-19 infected patients," adding, "We plan to verify the treatment for moderate patients experiencing symptoms such as dyspnea, muscle pain, and joint pain caused by COVID-19 related Delta variants."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
